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Abstract
Background: The recommendation of artemisinin combination therapy (ACT) as first-line treatment for
uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their
recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of
non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.
Methods: This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of
uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country
of Gabon.
Results: Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria
(including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were
followed up. All evaluable patients (n=38) showed an adequate clinical and parasitological response on Day 28 after
oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to
moderate intensity and completely resolved by the end of study.
Conclusions: This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and
mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends
support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite
species differentiation, with artemether-lumefantrine in Gabon.
Trial Registration: ClinicalTrials.gov Identifier: NCT00725777
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Background
Effective treatment of malaria is one of the main tools to
control and eventually eradicate malaria. A plethora of
clinical trials demonstrating high efficacy, satisfying effect-
iveness, and good tolerability and safety of artemisinin
combination therapy (ACT) – the current first-line treat-
ment of falciparum malaria – has been conducted and
published over the past decade [1,2]. Treatment recom-
mendations for non-falciparum malaria have however
remained virtually unchanged since the introduction of
chloroquine more than five decades ago [3].
Plasmodium falciparum and to a lesser extent Plasmo-
dium vivax have attracted more scientific interest compared
to the other human plasmodial species due to their high
incidence, virulence and the emergence of drug resistant
isolates. Today Plasmodium ovale and Plasmodium
malariae are among the most neglected tropical diseases
particularly in sub-Saharan Africa. This fact is illustrated by
an analysis of clinical trials on P. ovale and P. malariae ma-
laria resulting in less than five interventional clinical trials
over the past 10 years, compared to 930 reports of clinical
trials for P. falciparum m a l a r i a[ 4 ] .M o r er e s e a r c ha c t i v i t i e s
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and improved control tools for these plasmodial infections.
Today chloroquine remains the standard of care for
P. malariae and P. ovale malaria due to its low cost and
sustained efficacy. ACT is recommended as first-line
treatment for P. falciparum malaria and for mixed plas-
modial infections [3]. Despite these official recommenda-
tions, ACT is used in many areas for the treatment of all
forms of malaria including non-falciparum infections.
This may be explained by the fact that non-falciparum
species often occur concurrently with P. falciparum as
mixed infections in sub-Saharan Africa [5-7], and that
clinicians prefer the prescription of an ACT for malaria
cases due to lacking or unreliable species differentiation.
Finally, chloroquine treatment is unpopular in many
parts of sub-Saharan Africa due frequently experienced
adverse effects, e.g. induced pruritus.
At present, artemether-lumefantrine is the most widely
used ACT worldwide with 130 million treatment courses
procured in 2010 [8]. Anecdotal evidence indicates that
artemether-lumefantrine may be highly efficacious against
P. malariae, P. ovale and mixed-species malaria, however,
a prospective evaluation is still lacking. Since artemether-
lumefantrine is used on a large scale for these indica-
tions in sub-Saharan Africa we assessed the efficacy of
artemether-lumefantrine in patients suffering from un-
complicated malaria due to non-falciparum species or
mixed malaria species infections presenting at two dis-
trict hospitals in the Central African country of Gabon.
Methods
This prospective study was performed in Gabon at the
Medical Research Unit of the Albert Schweitzer Hospital
in Lambaréné [9] and the Regional Hospital of Fougamou.
This Central African region is characterized by perennial
transmission of P. falciparum [10] and co-endemicity of
P. ovale and P. malariae [5]. Young children and pregnant
women are at highest risk for malaria associated morbidity
and mortality in this region [11-13]. Plasmodium
falciparum isolates are highly resistant to chloroquine
and sensitivity to antifolate anti-malarials has decreased
[14-16], hence ACT has become the first-line treatment of
malaria [17]. The study followed the principles of the Dec-
laration of Helsinki (5th revision) and was approved by the
regional ethics committee (CERIL). Written informed con-
sent was obtained prior to inclusion in the study from adult
participants or from a legal representative of children below
21 years of age, and assent was obtained where applicable.
Participants older than six months presenting with
fever or with a history of fever during the previous four
days and for whom malaria was confirmed by a thick
blood smear were considered for inclusion. Thick and
thin blood smears were performed and patients positive
for P. ovale, P. malariae or a mixed infection with more
than one plasmodial species (including P. falciparum) at
a density of below 200,000/μl blood were considered eli-
gible for enrolment.
Patients were excluded from this study when present-
ing with a clinical condition requiring hospitalization,
haemoglobin<7 g/dl, history of hypersensitivity to arte-
mether-lumefantrine, prior intake of any anti-malarial
medication, or current pregnancy or breastfeeding. Demo-
graphic data, medical history, physical examination, and
axillary temperature were recorded at inclusion. Blood was
obtained for haemoglobin measurement (HemoCue AB,
Ängelholm, Sweden), malaria diagnostics, and storage on
filter papers for molecular analysis. Axillary temperature
and blood films were sequentially taken twice daily (at
hours 0, 8, 24, 36, 48 and 60) during the treatment period.
Follow up visits were scheduled for clinical examination,
haemoglobin measurement, and malaria diagnostics on
Days 7, 14 and 28 after the start of treatment.
Oral treatment with the standard six doses artemether-
lumefantrine regimen (Coartem
W and Coartem Disper-
sible
W) was administered on three consecutive days.
Artemether-lumefantrine was given as tablets or dispers-
ible tablets under supervision with a small amount of
liquid and patients were encouraged to consume simul-
taneously fatty food following current recommenda-
tions by the manufacturer.
Due to the well-known limitations of microscopic mal-
aria species differentiation in routine laboratories in sub-
Saharan Africa, PCR analysis based on the sequence of
the small subunit ribosomal RNA (ssrRNA) gene and op-
tional sequencing were performed for final plasmodial
species classification. Capillary blood was collected on
filter paper (Whatmann
W) for subsequent PCR analysis.
DNA was extracted with a commercial extraction kit
(QIAamp DNA Blood Mini Kit, Qiagen) following manu-
facturer instructions and stored at −20°C for further ana-
lysis. Species-specific nested PCR for P. falciparum,
P. malariae, P. ovale curtisi and P. ovale wallikeri was car-
ried out as previously described [18-21]. In samples not
showing an amplicon for further species differentiation, a
fragment of caseinolytic protease C gene (clpc) or cyto-
chrome b gene was amplified by nested PCR [22] and sub-
sequently sequenced on an ABI3100 Genetic Analyzer.
The primary objective was to assess the efficacy of
artemether-lumefantrine for the treatment of non-
falciparum and mixed plasmodial infections. The pri-
mary efficacy endpoint was the adequate clinical and
parasitological response on Day 28. Re-appearing parasit-
aemia was further classified by PCR genotyping as treat-
ment failure or newly acquired infection [19] except for
P. ovale infections where potential relapse from liver hyp-
nozoites precludes such a distinction. Secondary endpoints
included descriptive assessment of safety, tolerability, para-
site clearance time (PCT) and fever clearance time (FCT).
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to demonstrate a lower 90% confidence interval of ad-
equate clinical and parasitological response of at least
90% with a power of 0.8 assuming more than 98% effi-
cacy on day 28. The intention to treat population (ITT)
was defined as primary outcome for tolerability and
safety analysis and comprised of all patients included in
the study. Per protocol population (PP) was defined as
primary efficacy outcome and consisted of all patients
having received a full course of study medication who
were not prematurely withdrawn from follow up.
Data were captured on paper case record forms and tran-
scribed to an electronic database. All data were checked
manually and further statistical analysis was performed
using JMP 5.0 (SAS Institute Inc., NC, USA). Descriptive
statistics of baseline characteristics and outcome measures
were computed.
Results
Between July 2008 and July 2010, 40 patients were
included in this study. One patient decided to withdraw
consent before treatment initiation and another partici-
pant was excluded from the final analysis because of
reported concomitant chloroquine intake. All 39 patients
completed 28 day follow up and final analysis was done
for 38 patients (15 female participants, 39%). The age of
patients ranged from two to 50 years, with eight patients
aged less than five years and 19 between five and 12 years
of age. Baseline parasitaemia ranged from 31 – 100,680
trophozoites per microliter capillary blood (median 777/μl)
(Table 1). Based on microscopy thirty-two patients had
mixed-species infections and 7 patients presented with a
non-falciparum mono-infection.
Eight hours after initiation of anti-malarial treatment 12
(32%) patients had cleared parasites in peripheral blood.
Further 19 patients (50%) showed parasite clearance at 24
hours and all patients (100%) had cleared parasites within
36 hours. Median parasite clearance time was 24 hours.
Median parasite clearance time was comparable in chil-
dren below 5 years of age and adults (Table 2). Patients
with higher parasite densities on inclusion had longer
parasite clearance times. Only a minority of patients pre-
sented with fever at inclusion (n=5, 13%) and all cleared
fever within 36 hours after initiation of treatment. All eva-
luable patients had an adequate clinical and parasitological
response on Day 28 and the overall cure rate was therefore
100% (95% CI: 91-100%).
Tolerability and safety of the artemether-lumefantrine
was assessed for all patients from inclusion to Day 28.
No serious adverse event was recorded in the course of
this clinical trial and eight patients experienced adverse
events (diarrhoea, urinary tract infection, convulsion,
vomiting, cephalgia, abdominal pain, fever, and lymph-
adenopathy). Five adverse events were of mild severity
(urinary tract infection, vomiting, cephalgia, abdominal
pain), the other three adverse events were of moderate
severity, and all adverse events completely resolved by
the end of follow-up. The only adverse event considered
as possibly study drug related was the occurrence of one
episode of vomiting on day 1 after first drug administration.
Capillary blood was obtained and further tested by PCR
for molecular species differentiation. In this analysis 19
out of 39 samples were confirmed as non-falciparum or
mixed species infection. In the remaining 20 samples PCR
analysis demonstrated amplification of P. falciparum iso-
lates only and no amplification of non-falciparum parasite-
specific amplicons. Presence of P. malariae mono-
Table 1 Patient characteristics
Study flow
Patients included 40 100%
Evaluable patients 38 95%
Baseline characteristics
Females 15 39%
Age
1 8 5-14
Children<5 years of age 8 21%
Systolic blood pressure (mmHg)
1 100 90-110
Heart rate (/min)
1 88 68-104
Haemoglobin (g/dl)
1 11.3 10.1-12.4
Haemoglobin in children<5 years (g/dl)
1 11.5 10.0-12.6
Haemoglobin in patients>5 years (g/dl)
1 11.3 10.2-12.6
Asexual parasitaemia
1 777 266-3053
Asexual parasitaemia in children<5 years
1 480 278-742
Asexual parasitaemia in patients>5 years
1 849 225-6400
Participants presenting with fever 5 13%
1 median, interquartile range.
ACPR adequate clinical and parasitological response.
95% CI 95% confidence intervals.
Table 2 Patient outcomes
Outcome Parameters
Patients with ACPR (n, 95% CI) 38 91-100%
Parasite clearance time (hours)
1 24 8-24
Parasite clearance time in children<5 years (hours)
1 24 24-33
Parasite clearance time in patients>5 years (hours)
1 24 8-24
Fever Clearance Time (n=5, hours)
1 8 8-30
Patients experiencing any serious adverse event 0 0%
Patients experiencing any adverse event 8 20%
Haemoglobin D28 (g/dl)
1 11.6 10.6-12.3
Haemoglobin D28 in children<5 years (g/dl)
1 11.1 10.6-12.5
Haemoglobin D28 in patients>5 years (g/dl)
1 11.7 10.5-12.2
1 median, interquartile range.
ACPR adequate clinical and parasitological response.
95% CI 95% confidence intervals.
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one and 18 samples, respectively. Mixed infections were
confirmed by PCR analysis indicating co-infection with
P. falciparum and P. ovale (n=12, 63%), P. falciparum and
P. malariae (n=3, 16%) and concurrent occurrence of all
three species in three samples (n=3, 16%). P. ovale curtisi
(n=9) as well as P. ovale wallikeri (n=10) isolates were
present in the samples, concurrent presence of P. ovale
curtisi and P. ovale wallikeri was found in four patients.
Discussion
This is the first prospective assessment of artemether-
lumefantrine in the treatment of P. ovale, P. malariae
and mixed-species infection with P. falciparum.T h e
results demonstrate rapid parasite and fever clearance
when assessed twice daily and a reassuringly high cure
rate of 100% on Day 28. No clinical or parasitological
treatment failure occurred during the 28 day follow up
period. The primary hypothesis of an adequate clinical
and parasitological response rate above 90% could,
therefore, be confirmed. Although – at least in theory –
the occurrence of recrudescent parasitaemia after Day
28 cannot be ruled out, a longer follow-up period was
precluded due to the potential for relapse of P. ovale
infections and associated problems in classification as
treatment failure or reinfection in such circumstances.
Anti-relapse therapy with primaquine in P. ovale infec-
tion is not commonly prescribed in Gabon due to the
high risk for reinfection and safety concerns in G6PD
deficient individuals.
A limitation of the study design may be seen in the
lack of a control group. However, due to frequent occur-
rence of mixed infections including P. falciparum, a ran-
domized controlled trial design comparing standard
chloroquine treatment with artemether-lumefantrine was
precluded due to concerns for patients’ safety. Future
randomized clinical trials evaluating different forms of
ACT versus chloroquine in the treatment of P. malariae
or P. ovale mono-infections would however be highly
desirable. Despite recent reports of delayed parasite clear-
ance of P. malariae and P. ovale to chloroquine the cura-
tive efficacy of this drug appears to be maintained [23]. In
analogy to mixed malaria infections of P. falciparum with
P. malariae and P. ovale in Africa, co-endemicity of
P. vivax and P. falciparum in South East Asia requires
more rigorous assessment of the use of ACT in general,
and artemether-lumefantrine in particular, for the treat-
ment of P. vivax malaria [24,25]. Solid evidence of the
efficacy of ACT in the treatment of non-falciparum
malaria is essential before removal of chloroquine from
the market as a cheap over the counter drug taken for
undiagnosed and undifferentiated malaria cases.
The discrepancy between microscopic and molecular
species classification as observed in this study is striking
but not unexpected. Firstly, microscopic determination
of mixed infections is prone to misclassification due to
the relative predominance of P. falciparum trophozoites
and often low parasitaemia of the non-falciparum spe-
cies. Microscopic assessment may, therefore, under- or
over- estimate mixed species infections. To minimize
this source of misclassification internal and external
quality control systems for microscopic malaria diagnosis
are present in most African malaria research institutions,
but not in smaller hospitals or other primary care facil-
ities. In this study, microscopists were under external
quality assessment and an expert senior microscopist
was available to decide on discrepant results. However,
despite these measures a significant proportion of patients
showed discrepant results in microscopy and PCR. This
d i s c r e p a n c yi sl i k e l yt ob ee v e nm o r ei m p o r t a n ti nr o u -
tine laboratories without the additional quality control
mechanisms. This fact further underlines potential advan-
tages of a single treatment algorithm for all plasmodial
species since misclassification may lead to the prescription
of inadequate and potentially ineffective anti-malarials.
Molecular determination of non-falciparum and mixed
species infection may also lead to misclassification. The
phenomenon of low sensitivity for the detection of mixed
species and non-falciparum infections by PCR was previ-
ously described and may be explained by multiple factors
[26]. DNA recovery of low-level parasitaemia in mixed
infections may be too low, potentially leading to an under-
estimation of mixed infections. Use of frozen blood sam-
ples instead of filter paper sampling may improve the yield
of DNA extraction and should be compared to dried blood
samples in future studies of mixed infections. Most im-
portantly, no difference in the clinical or parasitological re-
sponse was noticed for PCR confirmed and un-confirmed
cases. Hence, artemether-lumefantrine is as an excellent
option for the treatment of patients with non-falciparum
and mixed species infection. Since the prevalence of
chloroquine resistance in Gabon is almost 100% [27],
chloroquine treatment of those patients with sub-
microscopic P. falciparum and microscopically detected
non-falciparum mixed infection (n=6 (15%) in this study)
is likely to fail.
This data support the current practice of using
artemisinin-combination therapy for the treatment of
non-falciparum and mixed plasmodium infections or
indeed clinically suspected malaria without prior species
diagnosis in Central Africa. Besides high efficacy, proven
safety and tolerability of artemether-lumefantrine, the use
of this combination may also reduce the risk of treatment
failure due to misdiagnosis of plasmodial species. However,
contrary to our findings, two recent reports of clinical
failures of artemether-lumefantrine treatment of P.
falciparum and P. malariae mixed infections challenge
this assumption [28,29]. Whether these reports are the rare
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stitutes a significant problem needs further evaluation.
Non-falciparum infections and mixed plasmodial spe-
cies infections constitute a common infectious disease
entity in tropical regions. In the setting of this study these
infections account for an estimated 5-10% of malaria cases
indicating the importance of non-falciparum and mixed
species infections. With the exception of the recently con-
ducted clinical development program of pyronaridine-
artesunate combination therapy for the treatment of vivax
malaria [30], non-falciparum malaria has been utterly
neglected in anti-malarial drug development until these
days accounting for less than 1% of published anti-malarial
trials [4]. The conduct of clinical trials providing more evi-
dence on the appropriate treatment of such infections
therefore seems mandatory.
Conclusions
In conclusion, this report constitutes the first prospective
assessment of artemether-lumefantrine in the treatment
of P. ovale, P. malariae, and mixed-species malaria. The
demonstrated high cure rate of 100% and the proven
favourable tolerability profile of artemether-lumefantrine
lend support to the approach of treating non-falciparum
or mixed species malaria or indeed all cases of malaria
without the possibility of species differentiation with
artemether-lumefantrine combination therapy in the
Central African country of Gabon.
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